News Releases
FARAPULSE featured prominently at 2019 HRS Scientific Sessions
Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation
FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System
Menlo Park, California – May 8, 2019 – FARAPULSE Inc. (“FARAPULSE” or “the “Company”) today announced it has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its Endocardial Ablation System.
